AbstractToday treatment of premenstrual syndrome (PMS) is still debatable and requires an individual differentiated approach. The objective of research was to evaluate the effectiveness of differentiated treatment of PMS various forms. Material and methods. The study involved 200 women of reproductive age with diagnosis of PMS. Combined estrogen-progestagen drugs with drospirenone, selective serotonin reuptake inhibitors, Vitex agnus castus extract or traditional treatment were prescribed according to the form and severity of disease. Results of the research. Traditional therapy was quite effective for correction of psychological and somatic symptoms in patients with mild neuropsychic and edematous forms of PMS. However, it was not effective enough in the patients with severe PMS and persons with cephalgic and crisis forms. Differentiated treatment of neuropsychical and edematous forms with combined oral contraceptives containing drospirenone and the use of selective serotonin reuptake inhibitors in patients with cephalgic and crisis forms of PMS significantly helped to reduce the intensity and leveling of symptoms compared with traditional therapy. Herbal medicines with Vitex agnus castus were effective for correction of symptoms in women with mild neuropsychical form. Conclusions. Treatment of patients with PMS should be individual and differentiated and depend on the clinical form and severity of the disease.
He Z, Chen R, Zhou Y, Geng L, Zhang Z, Chen S et al. Treatment for premenstrual syndrome with Vitex agnus castus: A prospective, randomized, multi-center placebo controlled study in China. Maturitas. May, 2009. 20; 63(1): 99-103.
Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2009 Apr 15; (2): CD006586.
Marjoribanks J, Brown J, O'Brien PM, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2013 Jun 7;6:CD001396. doi: 10.1002/14651858.CD001396.pub3.
Ministry of Public Health of Ukraine. Order #676 “Approval of clinical protocols for obstetric and gynecological care”. 2004.
Nevatte T, O'Brien PM, Bäckström T, Brown C, Dennerstein L, Endicott J et al. ISPMD consensus on the management of premenstrual disorders. Arch Womens Ment Health. 2013 Aug; 16(4): 279-91.
Panay N. Treatment of premenstrual syndrome: a decision-making algorithm. Menopause Int. 2012 Jun; 18(2): 90-2.
Rapkin AJ, Sorger SN, Winer SA. Drospirenone/ethinyl estradiol. Drugs Today (Barc). 2008 Feb; 44(2): 133- 45.
Rapkin AJ. New treatment approaches for premenstrual disorders. Am J Manag Care. 2005 Dec; 11(16 Suppl): 480-91.
Shah NR, Jones JB, Aperi J, Shemtov R, Karne A, Borenstein J. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet Gynecol. 2008 May; 111(5): 1175-82.
Smetnik VP, Tymilovich LG. Non-operative Gynecology: Guidance for doctors. Book 1. 1995; 129-38.
Zamani M, Neghab N, Torabian S. Therapeutic effect of Vitex agnus castus in patients with premenstrual
syndrome. Acta Med Iran. 2012; 50(2): 101-6.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.